Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELX 02

Drug Profile

ELX 02

Alternative Names: ELX-02; Synthetic aminoglycoside

Latest Information Update: 17 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Aminoglycosides; Antifibrotics; Small molecules
  • Mechanism of Action Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I; Rett syndrome; Cystinosis; Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Cystinosis
  • No development reported Duchenne muscular dystrophy; Mucopolysaccharidosis I; Rett syndrome

Most Recent Events

  • 14 Jan 2020 Efficacy, adverse events and pharmacokinetics data from phase II trials in Cystinosis released by Eloxx Pharmaceuticals
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In volunteers) in Israel
  • 28 Dec 2019 No recent reports of development identified for phase-I development in Mucopolysaccharidosis-I(In volunteers) in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top